Onctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in its Phase I/II clinical trial evaluating ...
From antibody–drug conjugates (ADCs) moving into early-stage disease to arenavirus-based immunotherapies and ctDNA-guided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback